基于Pyridine的SARM1小分子抑制剂减轻由NADase活动引起的细胞死亡
Qingxuan Tang1,2,3,4,5, Hang Yin1,2,3,4,5
1State Key Laboratory of Membrane Biology, Tsinghua University, Beijing 100084, China.
Chemical communications (Cambridge, England)
|July 29, 2024
概括
研究人员开发了以胺为基础的抑制剂,向SARM1,这是神经退行的一个关键蛋白质. 化合物TH-408有效地阻断了SARM1活动和细胞死亡,显示了神经疾病的治疗前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 神经退行性疾病涉及复杂的分子途径.
- 骨肌瘤 (SARM1) 是神经元死亡的关键调解者.
- 准SARM1为神经系统疾病提供了潜在的治疗策略.
研究的目的:
- 发现和描述SARM1.1的新型基于皮里丁的抑制剂.
- 评估这些抑制剂在预防SARM1介导细胞死亡方面的有效性.
- 在神经退行性疾病模型中探索SARM1抑制的治疗潜力.
主要方法:
- 合成和选基于皮里丁的化合物.
- 在体外生化测试以确定抑制功效 (IC50).
- 使用各种生物模型进行基于细胞的测试,以评估SARM1介导的细胞死亡.
主要成果:
- 鉴定了一系列基于皮里丁的强效SARM1抑制剂.
- 化合物TH-408表现出显著的SARM1抑制活性,其IC50为0.46μM.
- 在各种模型中有效减少SARM1介导的细胞死亡.
结论:
- 以Pyridine为基础的化合物,以TH-408为例,是有效的SARM1抑制剂.
- 破坏SARM1激活为神经退行性疾病提供了一个有前途的治疗途径.
- 这项工作促进了对神经疾病背景下SARM1调节和NAD+代谢的理解.
更多相关视频
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
10.0K
14:28Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
12.4K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K